Intellia Therapeutics, Inc. (0JBU.L)
USD 6.56
(-6.43%)
USD 6.56
(-6.43%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.3 Billion USD | -14.42% |
| 2022 | 1.52 Billion USD | 17.43% |
| 2021 | 1.29 Billion USD | 91.4% |
| 2020 | 676.32 Million USD | 102.32% |
| 2019 | 334.28 Million USD | -3.75% |
| 2018 | 347.31 Million USD | -7.69% |
| 2017 | 376.23 Million USD | 25.84% |
| 2016 | 298.96 Million USD | 263.98% |
| 2015 | 82.13 Million USD | 668.08% |
| 2014 | 10.69 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.19 Billion USD | -5.4% |
| 2024 Q1 | 1.25 Billion USD | -3.18% |
| 2023 Q3 | 1.24 Billion USD | -6.04% |
| 2023 Q4 | 1.3 Billion USD | 4.63% |
| 2023 FY | 1.3 Billion USD | -14.42% |
| 2023 Q1 | 1.41 Billion USD | -6.72% |
| 2023 Q2 | 1.32 Billion USD | -6.68% |
| 2022 Q2 | 1.11 Billion USD | -7.68% |
| 2022 Q1 | 1.2 Billion USD | -7.08% |
| 2022 Q4 | 1.52 Billion USD | 40.17% |
| 2022 FY | 1.52 Billion USD | 17.43% |
| 2022 Q3 | 1.08 Billion USD | -2.34% |
| 2021 Q2 | 672.24 Million USD | -6.23% |
| 2021 Q4 | 1.29 Billion USD | -3.03% |
| 2021 Q1 | 716.89 Million USD | 6.0% |
| 2021 FY | 1.29 Billion USD | 91.4% |
| 2021 Q3 | 1.33 Billion USD | 98.58% |
| 2020 Q4 | 676.32 Million USD | 47.49% |
| 2020 FY | 676.32 Million USD | 102.32% |
| 2020 Q3 | 458.55 Million USD | -6.58% |
| 2020 Q2 | 490.83 Million USD | 55.94% |
| 2020 Q1 | 314.75 Million USD | -5.84% |
| 2019 Q1 | 344.36 Million USD | -0.85% |
| 2019 FY | 334.28 Million USD | -3.75% |
| 2019 Q4 | 334.28 Million USD | -3.56% |
| 2019 Q3 | 346.63 Million USD | -1.65% |
| 2019 Q2 | 352.44 Million USD | 2.35% |
| 2018 Q1 | 359.54 Million USD | -4.44% |
| 2018 FY | 347.31 Million USD | -7.69% |
| 2018 Q4 | 347.31 Million USD | 8.12% |
| 2018 Q3 | 321.23 Million USD | -5.46% |
| 2018 Q2 | 339.77 Million USD | -5.5% |
| 2017 Q4 | 376.23 Million USD | 51.0% |
| 2017 FY | 376.23 Million USD | 25.84% |
| 2017 Q1 | 279.26 Million USD | -6.59% |
| 2017 Q2 | 264.97 Million USD | -5.12% |
| 2017 Q3 | 249.17 Million USD | -5.96% |
| 2016 Q4 | 298.96 Million USD | -0.83% |
| 2016 FY | 298.96 Million USD | 263.98% |
| 2016 Q2 | 310.62 Million USD | 311.2% |
| 2016 Q3 | 301.46 Million USD | -2.95% |
| 2016 Q1 | 75.54 Million USD | -8.03% |
| 2015 Q2 | 24.15 Million USD | 0.0% |
| 2015 Q1 | - USD | -100.0% |
| 2015 FY | 82.13 Million USD | 668.08% |
| 2015 Q4 | 82.13 Million USD | -6.34% |
| 2015 Q3 | 87.7 Million USD | 263.11% |
| 2014 FY | 10.69 Million USD | 0.0% |
| 2014 Q4 | 10.69 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -56.426% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -38.827% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -67.246% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -686.07% |
| bluebird bio, Inc. | 619.16 Million USD | -110.119% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -933.801% |
| Imunon, Inc. | 21.91 Million USD | -5835.637% |
| Editas Medicine, Inc. | 499.15 Million USD | -160.637% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 95.124% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 61.229% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -8.532% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 59.987% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 7.665% |
| Verastem, Inc. | 149.71 Million USD | -768.952% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 98.395% |
| Waters Corporation | 4.62 Billion USD | 71.882% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 98.682% |
| Biogen Inc. | 26.84 Billion USD | 95.154% |
| Nektar Therapeutics | 398.03 Million USD | -226.852% |
| Perrigo Company plc | 10.8 Billion USD | 87.964% |
| Dynavax Technologies Corporation | 997.09 Million USD | -30.477% |
| Illumina, Inc. | 10.11 Billion USD | 87.133% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -4501.581% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -66.717% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -484.693% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -1880.48% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 80.984% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -686.945% |
| Evolus, Inc. | 188.99 Million USD | -588.355% |
| Adicet Bio, Inc. | 207.29 Million USD | -527.597% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -559.04% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 96.067% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -532.168% |
| FibroGen, Inc. | 423.52 Million USD | -207.175% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 87.913% |
| OPKO Health, Inc. | 2.01 Billion USD | 35.329% |
| Homology Medicines, Inc. | 47.05 Million USD | -2664.683% |
| Geron Corporation | 394.07 Million USD | -230.134% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 66.031% |
| Exelixis, Inc. | 2.94 Billion USD | 55.785% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -253.056% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -742.678% |
| Zoetis Inc. | 14.28 Billion USD | 90.893% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -121.166% |
| Abeona Therapeutics Inc. | 64 Million USD | -1932.713% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 94.276% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -2225.291% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 56.49% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 60.149% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -109.323% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 24.941% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -23.991% |
| Insmed Incorporated | 1.32 Billion USD | 2.17% |
| TG Therapeutics, Inc. | 329.58 Million USD | -294.729% |
| Incyte Corporation | 6.78 Billion USD | 80.818% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 29.098% |